PreComb Therapeutics AG is a privately held Swiss biotech company focused on in vitro cancer drug testing to improve cancer management. It’s automated microtumor-based profiling device will enable clinical institutions to integrate the technology on-site in the hospital. The test makes it possible to functionally evaluate multiple cancer drugs, drug combinations and drug concentrations directly on patient-derived micro-tumors to maximize treatment outcome.
PreComb is located in Hombrechtikon within the Greater Zurich Area. Close proximity to global leaders in engineering of Lab automation systems, to the technical and life-science universities of Zurich, Wädenswil and Rapperswil and to the Zurich Life-science cluster offers an attractive environment for the development of state-of-the-art diagnostic solutions.